KIORA PHARMACEUTICALS INC
KPRXDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
KIO-104
Macular Edema
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
Persistent Corneal Epithelial Defect
KIO-301
Retinitis Pigmentosa
100 μg KIO-301
Retinitis Pigmentosa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KIO-104 | Phase 2 | Macular Edema | - | - |
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) | Phase 2 | Persistent Corneal Epithelial Defect | - | - |
KIO-301 | Phase 2 | Retinitis Pigmentosa | - | - |
100 μg KIO-301 | Phase 2 | Retinitis Pigmentosa | - | - |
Retinitis Pigmentosa
2 drugs in this indication
Persistent Corneal Epithelial Defect
1 drug in this indication
Macular Edema
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in KIORA PHARMACEUTICALS INC's drug pipeline?→
CatalystAlert tracks 4 drug candidates in KIORA PHARMACEUTICALS INC's (KPRX) pipeline across Phase 2. Its lead program is KIO-104 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is KIORA PHARMACEUTICALS INC's next FDA catalyst?→
KIORA PHARMACEUTICALS INC's (KPRX) next tracked catalyst is a Phase 2 expected November 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KPRX biotech catalysts?→
Add KPRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow KIORA PHARMACEUTICALS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.